AIA Posts Strong 1st Half Performance on Lifting of Covid-19 Curbs
By P.R. Venkat
AIA Group's value of new business in the first half rose 37% on the year as the lifting of COVID-19 restrictions in mainland China saw strong growth in the insurance business.
AIA said Thursday that new-business value came in at $2.03 billion, while its new-business margin fell 4.5 percentage points, to 51%.
"The rapid reopening of Asian markets following the pandemic has been met with an increased demand for personalized life and health insurance, value-added services and high-quality advice," AIA Group Chief Executive Lee Yuan Siong said.
AIA said its financial position remained strong, with a free surplus at the end of June being $16.26 billion.
"The outlook for the external global macroeconomic environment is uncertain in the near term, but the long-term potential for our business remains immense," the insurer said.
Write to P.R. Venkat at venkat.pr@wsj.com
(END) Dow Jones Newswires
August 23, 2023 18:52 ET (22:52 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track